NCT05035173Completed
The LYSA (Linking You to Support and Advice) Trial
Women's Cancer Survivorship: The LYSA (Linking You to Support and Advice) Trial
Source: ClinicalTrials.gov · Last updated 4 Mar 2026
Brief summary (registry, in English)
This study's aim is to evaluate the feasibility of introducing a women's malignancy survivorship clinic incorporating symptom management through ePRO collection (complex intervention) into routine follow up care in patients with early-stage Hormone Receptor(HR)-positive breast and gynaecologic cancer post primary curative therapy.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 200 (actual)
- First submitted
- 26 Apr 2021
- Start date
- 13 Mar 2021
- Primary completion date
- 20 Sept 2023
- Lead sponsor
- University College Cork
- Diseases
- Endometrial cancer, Cervical cancer
- NCT number
- NCT05035173
What you commit to
- Study type: Interventional
- Participants enrolled: 200
- From 13 Mar 2021 to the primary completion date, 20 Sept 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who are not treated with curative intent as above.
Other illness
- Patients with premalignant disease.
Other
- Persons who, in the opinion of the researcher or supervising clinician, are unable to cooperate adequately with the study protocol.
- Recent (within 12 months) participation in a study/programme involving a lifestyle intervention (e.g diet, exercise, survivorship). Note: Per discretion of PI as to whether may impact the outcome of this study intervention.
Who the study is looking for
- Women aged \> or = 18 years.
- Ability to read and understand English.
- Access to internet.
- Early-stage breast/gynaecologic cancer within 12 months of completion of primary curative therapy:
- Breast cancer: Stage I-III hormone receptor-positive (defined as estrogen receptor and/or progesterone receptor ≥ 1%) and HER2-negative per ASCO-CAP guidelines on or recommended to commence adjuvant endocrine therapy during the study period.
- Cervical cancer: Stage I to III treated with curative intent.
- Endometrial cancer: treated with curative intent adjuvant radiotherapy +/- chemotherapy
Age in the registry: 18 years to - · Sex: Female · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cork University Hospital Coordinator of this site? Confirm its status | Cork | Ireland | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.